
Quarterly report 2022-Q1
added 12-23-2023
Checkmate Pharmaceuticals Net Debt 2011-2026 | CMPI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Checkmate Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -12.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.1 M | -12.1 M | -12.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.89 | - | $ 6.54 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 22.2 | - | $ 3.68 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Edesa Biotech
EDSA
|
-7.74 M | $ 15.9 | - | $ 50.8 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Evogene Ltd.
EVGN
|
-3.44 M | $ 0.76 | - | $ 27.9 M | ||
|
Exelixis
EXEL
|
-282 M | $ 44.69 | - | $ 12.1 B | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Galapagos NV
GLPG
|
-1.29 B | $ 27.86 | - | $ 2.69 B | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 7.91 | - | $ 6.83 B | ||
|
Harmony Biosciences Holdings
HRMY
|
-608 M | $ 31.05 | - | $ 1.79 B | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
ImmuCell Corporation
ICCC
|
3.77 M | $ 8.44 | - | $ 76.2 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 101.57 | - | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Immuron Limited
IMRN
|
-21.9 M | $ 0.81 | 0.3 % | $ 9.47 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Incyte Corporation
INCY
|
-3.06 B | $ 99.1 | - | $ 19.3 B | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
InMed Pharmaceuticals
INM
|
-8.52 M | $ 0.7 | - | $ 1.71 M | ||
|
INmune Bio
INMB
|
-23.7 M | $ 1.33 | - | $ 32.9 M | ||
|
Innoviva
INVA
|
-293 M | $ 23.05 | - | $ 1.55 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Innate Pharma S.A.
IPHA
|
-120 M | $ 1.48 | -0.67 % | $ 235 M | ||
|
Jaguar Health
JAGX
|
116 K | $ 7.88 | - | $ 18.4 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
KalVista Pharmaceuticals
KALV
|
-55.5 M | $ 26.67 | - | $ 1.44 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Kamada Ltd.
KMDA
|
-70.2 M | $ 8.11 | - | $ 260 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 2.98 | - | $ 4.91 M | ||
|
Krystal Biotech
KRYS
|
-487 M | $ 259.95 | - | $ 7.52 B | ||
|
Kazia Therapeutics Limited
KZIA
|
-5.43 M | $ 12.42 | - | $ 1.65 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
-71 M | $ 224.86 | - | $ 4.11 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Liquidia Corporation
LQDA
|
-72.5 M | $ 38.15 | - | $ 3.28 B | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.05 | - | $ 433 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M |